尼洛替尼一线治疗初诊慢性期慢性髓性白血病的疗效、安全性、依从性与生活质量:法国前瞻性观察研究
这项法国全国前瞻性观察研究纳入183例初诊慢性期慢性髓性白血病患者,评估尼洛替尼一线治疗在日常临床实践中的分子学反应、安全性、生活质量与依从性。
核心结论
- 法国全国队列提示尼洛替尼是慢性期慢性髓性白血病患者有价值的一线治疗选择。
研究设计与样本
- 前瞻性观察研究,纳入183例初诊慢性期慢性髓性白血病患者,接受尼洛替尼一线治疗。
主要发现
- 患者生活质量基线良好且随访期间稳定。
临床怎么用
- 日常实践中尼洛替尼一线治疗可获得高比例主要分子学反应且生活质量稳定。
- 需关注不耐受和无效导致的停药,以及心血管缺血事件风险。
局限性
- 为观察性研究,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This observational, prospective study assessed, in a daily clinical practice, the molecular response, safety, quality of life (QoL) and treatment adherence in 183 patients with chronic myeloid leukaemia in chronic phase (CML-CP), receiving nilotinib as first-line treatment. Premature study termination before 24 months of follow-up occurred in 61 patients (33·3%), and was essentially due to nilotinib treatment discontinuation (n = 53; 29%), motivated by treatment intolerance (n = 29; 15·8%) and inefficacy (n = 19; 10·4%). After 24 months of treatment, 112/122 patients (91·8%) had a molecular assessment, 95·5% of whom achieved a major molecular response (MMR), 32·1% achieved uMR4 , defined as an undetectable molecular disease with 4-log molecular response sensitivity (≥10 000 ABL1 transcripts). The Morisky Green Levine Medication Adherence Scale was completed by 94/122 patients (77·0%), and 89·4% of these patients obtained a satisfactory level of treatment adherence, defined as a score ≥3. Patients' QoL was good at baseline and stable during the follow-up period. The two most common nilotinib-related adverse events (AEs) were pruritus (14·8%) and asthenia (13·7%). Seven patients (3·8%) experienced at least one cardiovascular ischaemic AE. This French nationwide cohort study provides relevant information in daily clinical practice indicating that nilotinib is a valuable first-line treatment option for CML-CP patients.
引用
- Huguet F, Cayuela JM, Cambier N, et al. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Br J Haematol. 2019. PMID: 31394591. doi:10.1111/bjh.16145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。